Effect of Zoledronic Acid on Prevention of Bone Loss in Acute Phase First-ever Stroke Patients

  • STATUS
    Recruiting
  • End date
    Feb 28, 2023
  • participants needed
    56
  • sponsor
    Yonsei University
Updated on 28 January 2021

Summary

In order to reduce the incidence of fractures due to osteopenia, osteoporosis, and bone mineral density in first stroke patients, the purpose of this study was to determine whether it is meaningful to administer zoledronic acid prophylactically, and to define the characteristics of the patient group that can benefit.

Subjects suitable for the selection criteria are divided into an experimental group (zoledronic acid group) and a control group (physiological saline group) in random permuted blocks. Random assignment means that a coin is thrown and assigned to the experimental group or the control group with the probability of a head or tail, and is assigned using a random number table.

The comparison-control group was designed to analyze and compare whether there is a significant effect of preventing the decrease in bone density in the group administered zoledronic acid through the double-blind experimental group and the control group.

The reason why physiological saline was selected as a reference drug was to double-blind with zoledronic acid, because it does not affect the subject's bone density and has a very low possibility of side effects, and its transparent properties are similar to that of zoledronic acid.

Subjects undergo a bone density (BMD-Spine and femur, Whole Body Composition Assessment) test using DEXA (dual energy x-ray absorptiometry) through outpatient or hospitalization at the Department of Rehabilitation within one month after the onset of stroke.

Subsequently, the subject will receive a single infusion of zoledronic acid 5mg/100mL or physiological saline 100mL intravenously at the outpatient or inpatient ward depending on the group. Subsequently, the subject will receive a single infusion of zoledronic acid 5mg/100mL or physiological saline 100mL intravenously at the outpatient or inpatient ward depending on the group.

Each subject or guardian fills in the questionnaire form at the time of the first injection, 6 months and 12 months after the injection, and immediately sees the fractures, side effects, and changes in drugs taken from the last survey to the present.

At the first injection, 6 months and 12 months after the injection, the above examination (bone density) is performed through an outpatient department of rehabilitation medicine, and by type known to be related to zoledronic acid administration such as fractures during the period (primary fragile fracture, non-spine fragile fracture, Symptom fracture, spine fracture, etc.)

Details
Condition Cerebrovascular accident, Stroke, Stroke, cerebrovascular accidents, strokes, cerebral
Treatment Placebo, Zoledronic Acid
Clinical Study IdentifierNCT04652128
SponsorYonsei University
Last Modified on28 January 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Hemiplegia due to first-ever ischemic and/or hemorrhagic stroke
Stroke confirmed by CT or MRI
Acute/Subacute stage: less than 1months after onset
Men or women 65 years of age or older
T-score between -1.0 and -2.5 (osteopenia patients)
Previously walk independent
Initial stroke severity is mild to moderately severe to very severe with an initial NIHSS score of 5 or more after the onset
Unable to walk 1 week after stroke onset, (Functional Ambulatory Category [FAC]<2)
Severe motor function involvement (Total of FMA: < 50)
Written informed consent

Exclusion Criteria

Progressive or unstable stroke
Pre-existing and active major neurological disease
Previously diagnosed as osteoporosis
Lactating Mother or pregnant woman
Hypocalcemia(<8.8mg/dL or 2.1mmol/L), hypomagnesemia( <1.7 mg/dL or 0.7mmol/L) or Hypophosphatemia (<2.5 mg/dL or 0.81mmol/L)
History of Thyroid Surgery, Hypoparathyroidism or Small Intestine Excision
Fracture history of BMD site (L1-L5 or femur head)
Creatinine clearance rate <35 mL/min, Severe Renal Disease or under current treatment with an aminoglycoside antibiotic
Dehydration
Malabsorption States
History of Bronchial Asthma
Recent Invasive Dental Procedure
History of Aseptic Necrosis of Jaw Bone
A history of significant alcohol or drug abuse in the prior 3 years
Advanced liver, cardiac, or pulmonary disease
A terminal medical diagnosis consistent with survival < 1 year
Any Condition that would represent a contraindication to zoledronate, including allergy to zoledronate
Previous bisphosphonate administration history, including zoledronate
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note